7 days in healthcare (February 20th-26th, 2023)

Summary

From the point of view of Biomedicine, perhaps the most striking thing is that it is the 90th anniversary of the first transplant in humans, which took place in Kherson (Ukraine), a city that is so topical today due to the Russian invasion. It was a kidney transplant to a 26-year-old woman.

As regards Global Health, an important report on maternal mortality published by the United Nations. There is no decrease in frequency in recent years. Globally, 800 maternal deaths occur every day, a staggering figure. Cholera emerges globally, with outbreaks already in 30 countries, which indicates serious problems in water management and in the sanitary and hygienic conditions of the population.

Regarding International Health Policy, it seems that, despite the large outbreak of covid that occurred in China, after the abandonment of the covid-zero policy, this has not generated new variants of the virus. In the United Kingdom, conflicts persist in the NHS, with junior doctors joining the strikes. Important division in Colombia before the new health reform promoted by President Petro.

If we talk about National Health Policy (Spain), the cumulative incidence of covid continues to rise slightly, although mortality is decreasing. The medical conflict continues, both in Madrid and in other communities. The cost of putting a personal assistant to each Primary Care doctor is evaluated: 505 million euros. It’s a lot of money, but it’s possibly part of the solution. The pharmaceutical sector, with a large rise in 2022, consolidates as a large export sector in Spain.

At the Business level, internationally, Apple about to develop a smart watch that can detect blood glucose level, which can change diabetes management. Big Pharma is resisting at the international level that patents are expiring and giving way to generics, as reported by the Financial Times. It seems that Fresenius is going to concentrate on the area of hospitals and generics. In principle, the rumors of the possible sale of Quirón and the preparation of several private equity companies for this operation are dissipated. In Spain, significant increase in sales of Korian, Quirón and Asisa. BUPA and Mapfre alliance to sell certain insurance in some Latin American countries.

Biomedicine

Global Health

International Health Policy

National health policy

Companies